Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Sunesis is committed to advancing its lead drug candidate, QINPREZO (vosaroxin), through clinical trials. QINPREZO is an anti-cancer quinolone derivative, or AQD — a class of compounds that has not been used previously for the treatment of cancer.
Revenue (Q1, 2018)
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (25-May-2018)
Closing share price (25-May-2018)